Q1 2023 Non-GAAP Operating Income

AUSTEDO XR Approved in February 2023 ONCE-DAILY Austedo XR (deutetrabenazine) extended-release tablets Demonstrated efficacy* ✰ Three once daily dosing options available Patient sample titration pack available Q6 Q12 Q24 Teva's shared solutions program provides ongoing patient support Austedo R extended Once Daily Patient Titration Kit teva Now available in the U.S. for the treatment of TD and chorea for HD * The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry | 9| mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. teva

View entire presentation